T. Rowe Price Associates
EIGR

T. Rowe Price Associates’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

T. Rowe Price Associates’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,160
Closed -$18.4M – 2563
2015
Q1 		$18.4M Sell
2,160
-294
-12% -$2.57M ﹤0.01% 1163
2014
Q4 		$21.6M Buy
2,454
+217
+10% +$1.26M ﹤0.01% 1093
2014
Q3 		$10.5M Buy
+2,237
New +$11.8M ﹤0.01% 1294

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

T. Rowe Price Associates's EIGR Position: Q2 2015 in Review

T. Rowe Price Associates sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 2,160 shares — an estimated $18.4M sold.

T. Rowe Price Associates first reported a position in EIGR in Q3 2014 and held it in 3 quarters. The position peaked at $21.6M in Q4 2014. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

  • T. Rowe Price Associates reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,160 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $18.4M.
  • T. Rowe Price Associates first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 3 quarters.
  • T. Rowe Price Associates's Eiger BioPharmaceuticals, Inc. position peaked at $21.6M in Q4 2014.
  • 44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.